Basilea Pharmaceutica AG (BPMUF PINK) stock market data APIs
$47.9524
0(0%)
as of May 2, 2025
Basilea Pharmaceutica AG Financial Data Overview
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Prev. Close
47.9524
Open
47.9524
High
47.9524
Low
47.9524
52 wk Range
44.45-54
Market Cap
649 M
P/E Ratio
6.709
Shares Outstanding
12 123 K
Revenue
209 M
Beta
0.781
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Basilea Pharmaceutica AG data using free add-ons & libraries
Get Basilea Pharmaceutica AG Fundamental Data
Basilea Pharmaceutica AG Fundamental data includes:
- Net Revenue: 209 M
- EBITDA: 63 130 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Basilea Pharmaceutica AG News
New
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
Basilea Pharmaceutica AG Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of pat...
Basilea announces acquisition of preclinical antibiotics program from Spexis
Basilea Pharmaceutica AG Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allsc...
Basilea provides portfolio status update
Basilea Pharmaceutica AG Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024 Cresemba in-market sales of USD 445 million,...
Basilea announces accelerated loan repayment
Basilea Pharmaceutica AG Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
